For short-term use in patients with hemophilia to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction (injection only); treatment of cyclic heavy menstrual bleeding (oral only). Unlabeled use(s):
Treatment of GI hemorrhage, hereditary angioneurotic edema, primary or intrauterine device–induced menorrhagia, or recurrent epistaxis; prevention of perioperative bleeding or rebleeding after subarachnoid hemorrhage.
Factor IX complex concentrates, anti-inhibitor coagulant concentrates
Coadministration of tranexamic acid and factor IX complex concentrates or anti-inhibitor coagulant concentrates may increase the risk of thrombosis. Avoid coadministration.
Coadministration of tranexamic acid and hormonal contraceptives may exacerbate the increased thrombotic risk associated with combination hormonal contraceptives. Coadminister only if there is a strong medical need and if the benefit of treatment outweighs the potential for the increased risk of a thrombotic event. Additional clinical monitoring is warranted.
Tissue plasminogen activators
Coadministration may decrease the efficacy of both tranexamic acid and tissue plasminogen activators. Use with caution. Additional clinical monitoring is warranted.
Coadministration of tretinoin with tranexamic acid may increase the risk of severe thromboembolic reactions. Use with caution. Additional clinical monitoring is warranted.